Viremia
14
1
1
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
2 terminated out of 14 trials
77.8%
-8.7% vs benchmark
36%
5 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (14)
Differentiated Service Delivery for Pregnant and Postpartum Women Living With HIV and Their Infants
Adaptability of an Undetectable = Untransmissible Model for HBV
Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes
Enhanced Virologic Monitoring for Pregnant and Postpartum Women With HIV
Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV
Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)
Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without Source
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission
Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus
An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria
Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
Yellow Fever Virus Vaccine and Immune Globulin Study
Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus